Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer

JIN Huimin; LIN Lihong; ZHAO Zhen; GONG Xishuang

doi:10.3971/j.issn.1000-8578.2022.22.0211

Cancer Research on Prevention and Treatment > 2022 > 49(10): 1059-1064. > DOI: 10.3971/j.issn.1000-8578.2022.22.0211

JIN Huimin, LIN Lihong, ZHAO Zhen, GONG Xishuang. Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(10): 1059-1064. DOI: 10.3971/j.issn.1000-8578.2022.22.0211

Citation:

PDF (3011 KB)

Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer

1.
Department of Gynecology, Anyang Tumor Hospital, Anyang 455000, China
2.
Department of Gynecology, Anyang Maternal and Child Health Hospital, Anyang 455000, China

More Information

Corresponding author:
GONG Xishuang, E-mail: 15836345777@163.com
Received Date: March 06, 2022
Revised Date: July 21, 2022
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the efficacy and safety of anlotinib combined with PD-1 blockades for patients with advanced epithelial ovarian cancer (EOC).
Methods
A retrospective study was performed, enrolling 33 patients with advanced EOC who failed standard systematic therapy. All patients were administered with anlotinib combined with PD-1 blockades. The efficacy and safety profile were determined during treatment.
Results
The objective response rate of the 33 patients was 36.4% (95%CI: 20.4%-54.9%) and the disease control rate of the patients was 81.8% (95%CI: 64.5%-90.0%). The median PFS and OS of the 33-patient cohort were 7.6 months (95%CI: 3.1-12.1) and 19.6 months (95%CI: 15.1-24.1), respectively. The most common treatment-related adverse reactions were fatigue (66.7%), nausea and vomiting (54.5%), hypertension (48.5%), and diarrhea (39.4%). Furthermore, multivariate Cox regression analysis indicated that ECOG performance status and FIGO stage were independent factors for predicting the PFS of the combination regimen for patients with advanced EOC.
Conclusion
Anlotinib combined with PD-1 blockades preliminarily exhibit satisfactory efficacy and tolerable safety profile for patients with advanced EOC.
- Epithelial ovarian cancer,
- Anlotinib,
- PD-1 blockade,
- Efficacy,
- Adverse effect

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (23)

References

[1]	Rong Y, Li L. Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer[J]. J Ovarian Res, 2021, 14(1): 2. doi: 10.1186/s13048-020-00759-9
[2]	谭芳春, 李力. 卵巢癌分子分型及其临床应用的研究进展[J]. 肿瘤防治研究, 2018, 45(2): 106-109. doi: 10.3971/j.issn.1000-8578.2018.17.0771 Tan FC, Li L. Research progress on molecular typing of ovarian cancer and its clinical application[J]. Zhong Liu Fang Zhi Yan Jiu, 2018, 45(2): 106-109. doi: 10.3971/j.issn.1000-8578.2018.17.0771
[3]	Champer M, Huang Y, Hou JY, et al. Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence[J]. Gynecol Oncol, 2018, 148(1): 19-27. doi: 10.1016/j.ygyno.2017.11.008
[4]	Oronsky B, Ray CM, Spira AI, et al. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer[J]. Med Oncol, 2017, 34(6): 103. doi: 10.1007/s12032-017-0960-z
[5]	Singh N, Badrun D, Ghatage P. State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer[J]. Expert Opin Pharmacother, 2020, 21(13): 1579-1590. doi: 10.1080/14656566.2020.1775813
[6]	Ni J, Cheng X, Chen J, et al. Anlotinib as Exploratory Therapy for Platinum-Resistant OvarianCancer: A Retrospective Study on Efficacy and Safety[J]. Onco Targets Ther, 2020, 13: 9857-9863. doi: 10.2147/OTT.S268613
[7]	Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer[J]. N Engl J Med, 2003, 348(3): 203-213. doi: 10.1056/NEJMoa020177
[8]	Hwang WT, Adams SF, Tahirovic E, et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis[J]. Gynecol Oncol, 2012, 124(2): 192-198. doi: 10.1016/j.ygyno.2011.09.039
[9]	Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phaseⅡ KEYNOTE-100 study[J]. Ann Oncol, 2019, 30(7): 1080-1087. doi: 10.1093/annonc/mdz135
[10]	Hamanishi J, Mandai M, Ikeda T, et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer[J]. J Clin Oncol, 2015, 33(34): 4015-4022. doi: 10.1200/JCO.2015.62.3397
[11]	Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247. doi: 10.1016/j.ejca.2008.10.026
[12]	Miller TP, Fisher BT, Getz KD, et al. Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events[J]. Pediatr Blood Cancer, 2019, 66(7): e27747. doi: 10.1002/pbc.27747
[13]	Harries M, Gore M. PartⅠ: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis[J]. Lancet Oncol, 2002, 3(9): 529-536. doi: 10.1016/S1470-2045(02)00846-X
[14]	Cui Q, Hu Y, Ma D, et al. A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer[J]. Drug Des Devel Ther, 2021, 15: 339-347. doi: 10.2147/DDDT.S286529
[15]	Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028[J]. Gynecol Oncol, 2019, 152(2): 243-250. doi: 10.1016/j.ygyno.2018.11.017
[16]	Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. doi: 10.1056/NEJMoa1915745
[17]	Liu JF, Herold C, Gray KP, et al. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial[J]. JAMA Oncol, 2019, 5(12): 1731-1738. doi: 10.1001/jamaoncol.2019.3343
[18]	Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J]. Cancer Sci, 2018, 109(4): 1207-1219. doi: 10.1111/cas.13536
[19]	Rades D, Motisi L, Veninga T, et al. Predictors of Outcomes and a Scoring System for Estimating Survival in Patients Treated With Radiotherapy for Metastatic Spinal Cord Compression From Small-Cell Lung Cancer[J]. Clin Lung Cancer, 2019, 20(4): 322-329. doi: 10.1016/j.cllc.2019.04.005
[20]	Yan Z, Gu YY, Hu XD, et al. Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism[J]. Oncol Lett, 2020, 20(3): 3035-3045. doi: 10.3892/ol.2020.11857
[21]	Domchek SM, Aghajanian C, Shapira-Frommer R, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy[J]. Gynecol Oncol, 2016, 140(2): 199-203. doi: 10.1016/j.ygyno.2015.12.020
[22]	Yuan M, Zhu Z, Mao W, et al. Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study[J]. Front Oncol, 2021, 11: 683502. doi: 10.3389/fonc.2021.683502
[23]	Jiang FE, Zhang HJ, Yu CY, et al. Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study[J]. Neoplasma, 2021, 68(4): 861-866. doi: 10.4149/neo_2021_201228N1415

[1]	SU Yudong, CHEN Jinliang, CHEN Peng. Rare Adverse Reaction to Anlotinib in Treatment of Thoracic Carcinoma: A Case Report of Dry Eye Syndrome[J]. Cancer Research on Prevention and Treatment, 2024, 51(12): 1057-1060. DOI: 10.3971/j.issn.1000-8578.2024.24.0726
[2]	MA Junyan, WU Qiong, DONG Liang, LI Chunyang, WANG Zhiwu. Construction and Validation of A Predictive Model Including TCM Pathogenic Syndrome for Short-term Efficacy of PD-1 Inhibitors in Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(10): 960-967. DOI: 10.3971/j.issn.1000-8578.2023.22.1513
[3]	ZHANG Xiaojuan, YUE Dongli, YANG Shuangning, HAO Na, WANG Liping, DONG Wenjie. Efficacy of Combination of Camrelizumab with Anlotinib as Third-line Therapy for Patients with Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(6): 593-597. DOI: 10.3971/j.issn.1000-8578.2023.22.0098
[4]	WEI Zongjie, KUANG Youlin, CHEN Yong, WANG Lu, CHEN Xiao, GOU Xin. Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(7): 698-702. DOI: 10.3971/j.issn.1000-8578.2022.21.1340
[5]	YU Xuxu, LI Xiangke, YANG Minjie, CHEN Zhong, MAO Yinggang, SONG Lijie. Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(10): 974-978. DOI: 10.3971/j.issn.1000-8578.2021.21.0271
[6]	YANG Jing, WANG Yang, FENG Xiucheng, CAI Hongbing. Adverse Reaction of HIPEC Combined with Intravenous Chemotherapy on Ovarian Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2019, 46(12): 1131-1135. DOI: 10.3971/j.issn.1000-8578.2019.19.0324
[7]	HOU Wenjie, XU Jianying, CHI Chi, MAO Min, ZHANG Yueming, CHEN Youguo. Comparison of Efficacy and Safety Between Liposome-paclitaxel plus Carboplatin and Paclitaxel plus Carboplatin on Epithelial Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2018, 45(6): 410-413. DOI: 10.3971/j.issn.1000-8578.2018.17.1516
[8]	YAO Weirong, WAN Huiping, YU Yanmin, LUO Lifang, ZHANG Xiquan, TANG Zhimou. Effects of Stability Plasma Concentration of 5-Fu and Docetaxel on Adverse Events and Short Term Effect after 5-Fu and Docetaxel Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2014, 41(01): 53-56. DOI: 10.3971/j.issn.1000-8578.2014.01.012
[9]	Shen Wenbin, Zhu Shuchai, Gao Hongmei, Li Juan, Su Jingwei, Liu Zhikun, Li Youmei, Wan Jun. Toxic Effect and Long-term Survival of Three Dimensional Conformal High-dose Radiotherapy for Non- small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(05): 577-581. DOI: 10.3971/j.issn.1000-8578.2012.05.021
[10]	HU Zheng-cao, LI Yong-jie, CHEN Su-mei. Clinical Study on Effect of Yanshu Injection in Efficacy Enhancing and Toxicity Reducing of Chemotherapy in Patients with Malignant Tumor[J]. Cancer Research on Prevention and Treatment, 2011, 38(12): 1429-1430. DOI: 10.3971/j.issn.1000-8578.2011.12.023

Cited By

Cited by

Periodical cited type(1)

闫红华. 能谱CT定量对肝脓肿和肝细胞癌的鉴别诊断价值分析. 影像研究与医学应用. 2025(08): 108-111 .

Other cited types(0)

Figures(3) / Tables(4)

Get Citation

PDF

XML

Article views (2256) PDF downloads (445) Cited by(1)

Turn off MathJax

Article Contents

Abstract

References

Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer